BaconRNewmanSRankinLPitcairnGWhitingR. Pulmonary and nasal deposition of ketorolac tromethamine solution (SPRIX) following intranasal administration. Int J Pharm. 2012;431(1-2):39-44.
2.
BuckleyMMBrogdenRN. Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1990;39(1):86-109.
3.
JalladNSGargDCMartinezJJMroszczakEJWeidlerDJ. Pharmacokinetics of single-dose oral and intramuscular ketorolac tromethamine in the young and elderly. J Clin Pharmacol. 1990;30(1):76-81.
4.
JungDMroszczakEBynumL. Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. Eur J Clin Pharmacol. 1988;35(4):423-425.
5.
MatavaMBraterDCGritterN. Recommendations of the National Football League Physician Society Task Force on the use of Toradol® ketorolac in the National Football League. Sports Health. 2012;4(5):377-383.
6.
McAleerSDMajidOVenablesEPolackTSheikhMS. Pharmacokinetics and safety of ketorolac following single intranasal and intramuscular administration in healthy volunteers. J Clin Pharmacol. 2007;47(1): 13-18.
7.
MroszczakEJJungDYeeJBynumLSeveliusHMasseyI. Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. Pharmacotherapy. 1990;10(6):33S-39S.
8.
SPRIX ® (Ketorolac Tromethamine) nasal spray. Shirley, NY: American Regent Inc.
